The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2-amplified biliary tract cancer (BTC).
 
Shubham Pant
Consulting or Advisory Role - Ipsen; Janssen; Novartis; Zymeworks
Research Funding - 4D Pharma (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); bionte (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Elicio Therapeutics (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); Mirati Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Purple Biotech (Inst); Rgenix (Inst); Xencor (Inst); Zymeworks (Inst)
 
Jia Fan
Consulting or Advisory Role - BeiGene
 
Do-Youn Oh
Consulting or Advisory Role - Arcus Biosciences; ASLAN Pharmaceuticals; AstraZeneca; Basilea; Bayer; BeiGene; Celgene; Genentech/Roche; Halozyme; IQVIA; Merck Serono; Novartis; Taiho Pharmaceutical; Turning Point Therapeutics; Yuhan; Zymeworks
Research Funding - Array BioPharma; AstraZeneca; BeiGene; Handok; Lilly; MSD; Novartis; SERVIER
 
Hye Jin Choi
Consulting or Advisory Role - AstraZeneca; Roche
 
Jin Won Kim
Consulting or Advisory Role - AstraZeneca; BeiGene Beijing; BeiGene Beijing; BeyondBIO; Bristol-Myers Squibb/Celgene; Eisai; GC Cell; MSD; Ono Pharmaceutical; Roche; Sanofi; Servier; TCUBEit
 
Heung-Moon Chang
Research Funding - Astellas Pharma (Inst); Celgene (Inst); Taiho Oncology (Inst); Zymeworks (Inst)
 
Lequn Bao
No Relationships to Disclose
 
Hui-Chuan Sun
Employment - Zhongshan Hospital, Fudan University
Honoraria - AstraZeneca; Bayer; BeiGene; Eisai; Hengrui Pharmaceutical; Innovent Biologics; MSD; Roche; TopAlliance BioSciences Inc; Zelgen
Research Funding - Innovent Biologics (Inst); MSD (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Radiomic features to predict tumor response to systemic therapy in liver cancer patients (Inst)
 
Teresa Macarulla Mercade
No Relationships to Disclose
 
Feng Xie
No Relationships to Disclose
 
Jean Philippe Metges
No Relationships to Disclose
 
Ying Jieer
No Relationships to Disclose
 
John A Bridgewater
Honoraria - Incyte; SERVIER
Consulting or Advisory Role - AstraZeneca; Basilea; Bayer; Incyte; Merck Serono; Merck Serono; Roche; SERVIER; Taiho Oncology
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Celgene
Research Funding - Amgen; Incyte (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb/Medarex; Merck Serono; MSD Oncology; SERVIER
 
Mohamedtaki Abdulaziz Tejani
Consulting or Advisory Role - Exelixis
Speakers' Bureau - Natera
Research Funding - Bayer (Inst)
 
Emerson Yu-sheng Chen
Other Relationship - Horizon CME; Taiho Pharmaceutical
 
Harpreet Singh Wasan
Honoraria - Array BioPharma; Celgene; ERYTECH Pharma; Incyte; Merck KGaA; Roche/Genentech; Servier; Sirtex Medical; Zymeworks
Consulting or Advisory Role - Bayer; ERYTECH Pharma; Incyte; Pfizer; Pierre Fabre; Roche Pharma AG; Shire; Sirtex medical
Speakers' Bureau - Celgene; Incyte; Merck KGaA; SERVIER; Sirtex Medical
Research Funding - Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Sirtex Medical (Inst)
Expert Testimony - Oncosil
 
Michel Pierre Ducreux
Employment - Sandoz (I)
Honoraria - Bayer; Pierre Fabre; Roche/Genentech; TERUMO
Consulting or Advisory Role - Amgen; AstraZeneca; Basilea; Bayer; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; HalioDx; Ipsen; Lilly; Merck Serono; MSD; Novartis; Pierre Fabre; Rafael Pharmaceuticals; Roche; Servier; Sotio; Zymeworks
Speakers' Bureau - Amgen; AstraZeneca; Bayer; GlaxoSmithKline; HalioDx; Lilly; Merck KGaA; MSD; Pierre Fabre; Roche; SERVIER
Research Funding - Keocyt (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bayer; Merck Serono; Pierre Fabre; Roche; SERVIER
 
Jia-Fang Ma
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
 
Phillip M. Garfin
Employment - Seagen; Zymeworks
Stock and Other Ownership Interests - mesoblast; Neoleukin Therapeutics; Seagen; Zymeworks
Travel, Accommodations, Expenses - Seagen
 
James J. Harding
Consulting or Advisory Role - Adaptimmune; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; Elevar Therapeutics; Exelixis; Hepion Pharmaceuticals; Imvax; Lilly; Medivir; Merck; QED Therapeutics; Zymeworks
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Codiak Biosciences (Inst); Debiopharm Group (Inst); Genoscience Pharma (Inst); Genoscience Pharma (Inst); Incyte (Inst); Lilly (Inst); Loxo (Inst); Novartis (Inst); Pfizer (Inst); Polaris (Inst); Yiviva (Inst); Zymeworks (Inst)